Matches in UGent Biblio for { ?s ?p Lupus anticoagulants (LAC) are associated with thromboembolic complications (TEC). LAC can be detected via their anticoagulant properties in coagulation tests and thrombin generation assays, via the peak height (PH) and lag time (LT). To assess the thrombotic risk in LAC-positive patients, we have presently expressed the LAC-activity quantitatively via PH/LT calibration curves, constructed for mixtures of monoclonal antibodies with LAC-activity against β2-glycoprotein I (β2GPI) and prothrombin, spiked in normal plasma. PH/LT was determined in plasma of LAC patients, with (n=38) and without (n=21) TEC and converted into arbitrary LAC-units on parallel calibration lines. Patient LAC-titers ranged from 0-200 AU/ml, with 5/59 patients being negative. In the positive LAC-titer population (54/59), LAC-titers and anti-β2GPI IgG titers correlated with TEC, with odds ratios of 3.54 (CI: 1.07-11.7) and 10.0 (CI: 1.98-50.6), respectively. In patients with single or combined low titers, useful predictions on thrombosis could be made only after additional measurements of the prothrombotic plasma markers soluble P-selectin and FVII. This layered strategy yielded PPV, NPV, sensitivity and specificity values around 90% in this subgroup. Hence, LAC- and anti-β2GPI IgG titers, when combined with selected markers of the hypercoagulable state, allow a relevant thrombotic risk assessment in nearly all LAC patients.. }
Showing items 1 to 1 of
1
with 100 items per page.
- aggregation abstract "Lupus anticoagulants (LAC) are associated with thromboembolic complications (TEC). LAC can be detected via their anticoagulant properties in coagulation tests and thrombin generation assays, via the peak height (PH) and lag time (LT). To assess the thrombotic risk in LAC-positive patients, we have presently expressed the LAC-activity quantitatively via PH/LT calibration curves, constructed for mixtures of monoclonal antibodies with LAC-activity against β2-glycoprotein I (β2GPI) and prothrombin, spiked in normal plasma. PH/LT was determined in plasma of LAC patients, with (n=38) and without (n=21) TEC and converted into arbitrary LAC-units on parallel calibration lines. Patient LAC-titers ranged from 0-200 AU/ml, with 5/59 patients being negative. In the positive LAC-titer population (54/59), LAC-titers and anti-β2GPI IgG titers correlated with TEC, with odds ratios of 3.54 (CI: 1.07-11.7) and 10.0 (CI: 1.98-50.6), respectively. In patients with single or combined low titers, useful predictions on thrombosis could be made only after additional measurements of the prothrombotic plasma markers soluble P-selectin and FVII. This layered strategy yielded PPV, NPV, sensitivity and specificity values around 90% in this subgroup. Hence, LAC- and anti-β2GPI IgG titers, when combined with selected markers of the hypercoagulable state, allow a relevant thrombotic risk assessment in nearly all LAC patients.".